Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P00488
UPID:
F13A_HUMAN
Alternative names:
Protein-glutamine gamma-glutamyltransferase A chain; Transglutaminase A chain
Alternative UPACC:
P00488; Q59HA7; Q8N6X2; Q96P24; Q9BX29
Background:
Coagulation factor XIII A chain, also known as Protein-glutamine gamma-glutamyltransferase A chain or Transglutaminase A chain, plays a pivotal role in blood coagulation. It is activated by thrombin and calcium ion, catalyzing the formation of cross-links between fibrin chains, which stabilizes the fibrin clot. This process is crucial for the final step of clot formation, ensuring the clot remains intact to stop bleeding.
Therapeutic significance:
Factor XIII subunit A deficiency, a rare hematologic disorder, highlights the protein's critical role in hemostasis. Patients exhibit a life-long bleeding tendency, impaired wound healing, and spontaneous abortion in women. Understanding the role of Coagulation factor XIII A chain could open doors to potential therapeutic strategies, offering hope for individuals suffering from this deficiency.